Malaria and HIV coinfection in sub-Saharan Africa: prevalence, impact, and treatment strategies

Tebit E Kwenti

1Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Buea, 2Regional Hospital Buea, Buea, Cameroon

Abstract: Malaria and HIV, two of the world's most deadly diseases, are widespread, but their distribution overlaps greatly in sub-Saharan Africa. Consequently, malaria and HIV coinfection (MHC) is common in the region. In this paper, pertinent publications on the prevalence, impact, and treatment strategies of MHC obtained by searching major electronic databases (PubMed, PubMed Central, Google Scholar, ScienceDirect, and Scopus) were reviewed, and it was found that the prevalence of MHC in SSA was 0.7%–47.5% overall. Prevalence was 0.7%–47.5% in nonpregnant adults, 1.2%–27.8% in children, and 0.94%–37% in pregnant women. MHC was associated with an increased frequency of clinical parasitemia and severe malaria, increased parasite and viral load, and impaired immunity to malaria in nonpregnant adults, children, and pregnant women, increased in placental malaria and related outcomes in pregnant women, and impaired antimalarial drug efficacy in nonpregnant adults and pregnant women. Although a few cases of adverse events have been reported in coinfected patients receiving antimalarial and antiretroviral drugs concurrently, available data are very limited and have not prompted major revision in treatment guidelines for both diseases. Artemisinin-based combination therapy and cotrimoxazole are currently the recommended drugs for treatment and prevention of malaria in HIV-infected children and adults. However, concurrent administration of cotrimoxazole and sulfadoxine–pyrimethamine in HIV-infected pregnant women is not recommended, because of high risk of sulfonamide toxicity. Further research is needed to enhance our understanding of the impact of malaria on HIV, drug–drug interactions in patients receiving antimalarials and antiretroviral drugs concomitantly, and the development of newer, safer, and more cost-effective drugs and vaccines to prevent malaria in HIV-infected pregnant women.

Keywords: malaria, HIV, coinfection, prevalence, treatment, sub-Saharan Africa

Introduction

Malaria and HIV, two of the most deadly diseases of our time,1,2 are still a major public health menace in sub-Saharan Africa (SSA). Both diseases are widespread, but their distribution greatly overlaps in SSA. Consequently, malaria and HIV coinfection (MHC) is common in the region. Malaria, a protozoan parasitic disease, accounted for 216 million cases and 445,000 deaths in 2016, approximately 90% of cases and deaths occurring in SSA,3 while HIV, a viral disease, accounted for 36.7 million cases and about 1 million deaths in 2016.4 SSA also has the lion’s share of the global HIV burden (approximately 70%).5 Both diseases affect the poorest segment of a population, made vulnerable by the lack of access to quality education, information, and state services, all characteristic of SSA. In effect, malaria and HIV could be said to be exacerbated and reinforced by poverty by affecting young people who would have otherwise enter
the workforce and contribute to the local economy. The coendemicity of malaria and HIV in SSA has generated so much interest in the study of both diseases recently, because of possible drug–drug interactions in MHC patients receiving malaria and HIV treatment concomitantly, as well as their impact on the control of either disease.6–8

Together, malaria and HIV account for over 2 million deaths globally every year.9,10 Children (especially those <5 years of age) and pregnant women are at greatest risk of malaria morbidity and death,11,12 and women and adolescent girls are the most vulnerable to HIV infection.4 Pregnant women and their unborn babies are at particular risk of MHC: approximately 1 million pregnancies are complicated by MHC every year in SSA,13 putting the life of the pregnant woman and her infant at risk. Adverse pregnancy outcomes associated with MHC include low birth weight, preterm delivery, higher rates of neonatal mortality, placental malaria infection, severe anemia, slow gestational development, reduced transfer of maternal antibodies (that confer protection against other infectious diseases) from mother to child, and in some cases increased risk of mother–child transmission of HIV.14,15

Studies had failed to demonstrate any meaningful interaction between malaria and HIV, but a recent study showed one that was synergistic and bidirectional,16 leading to an exponential increase in the adverse events caused by either infection. Studies suggest the effect of MHC is greater in patients with advanced and suppressed immune function. Malaria and HIV interact in different ways: 1) biologically, malaria in HIV-infected patients leads to an increase in viremia and a decline in CD4+ T-cell count, potentially worsening the clinical outlook of HIV-infected persons and promoting HIV transmission,17,18 and MHC persons are more likely to harbor parasites at a high density; 2) clinically, HIV contributes to more frequent and more severe malaria, commonly anemia and cerebral malaria,19 and increased risk of congenital infection, while malaria increases the disease progression of HIV to AIDS; 3) immunologically, malaria and HIV interact with the host’s immune system, leading to complex activation of immune cells and subsequent tightly regulated production of cytokines and antibodies; and 4) therapeutically, HIV infection can impair the efficacy of antimalarial treatment, increase adverse events, and select for parasites with drug-resistant mutations.19,21

There is sufficient evidence to show that MHC exponentially increases the adverse effects of one infection on the other, has a negative impact on the prognosis, and complicates the prevention and treatment of both infections in SSA. A clear understanding of both diseases and their interaction is necessary for effective control, particularly in SSA, where the burden is highest. This paper reviews the pertinent publications on the prevalence of MHC, the impact of MHC in terms of biological, clinical, immunological, and therapeutic outcomes (not leaving out the impact on the transmission of one on the other), and treatment strategies for malaria and HIV in MHC patients, and concludes with some future perspectives.

Methods
Multiple electronic databases – PubMed, PubMed Central, Google Scholar, ScienceDirect, and Scopus – were searched using the keywords “malaria”, “HIV”, “co-infection”, “prevalence”, “interaction”, “treatment”, and “SSA”. Reference sections in articles were also reviewed to find other relevant studies. Articles reporting the prevalence of MHC, interaction between malaria and HIV, treatment of malaria in HIV-coinfected patients and vice versa in SSA published up to 2018 were included for data extraction.

Prevalence of malaria and HIV coinfection (MHC) in SSA
Geographically, malaria and HIV are concentrated in tropical and subtropical regions of the world, including SSA. Approximately 70% of the world’s HIV-infected population lives in SSA, where 350 million people are exposed to infection with malaria.22,23 Because of this overlapping distribution, MHC is to be expected. A systematic review of HIV1 infection in Africa revealed malaria to be the third-highest cause of HIV-related morbidity.24 Studies conducted in this region have demonstrated heterogeneity in the distribution of MHC. Reported prevalence varies considerably across different populations and geographical settings in SSA. A majority of studies published thus far have reported MHC prevalence in adults (including nonpregnant women), while few have been conducted on children and pregnant women, thereby leaving a void in our understanding of the epidemiology of MHC in these groups (Table 1). Generally, MHC prevalence is 0.7%–72% in SSA: 0.7%–47.5% in nonpregnant adults, 1.2%–27.8% in children, and 0.94%–37% in pregnant women. A meta-analysis performed in 2016 revealed overall pooled prevalence of MHC in SSA was 19%, 26% in adults, 12% in pregnant women, and 9% in children.25 Most studies (but not all)26 conducted so far have failed to observe any significant association between MHC and sex or age.

Studies that have been conducted in SSA rarely report the infecting Plasmodium spp. in MHC (Table 1). Just a
### Table 1 Summary of studies reporting the prevalence of malaria and HIV coinfection in SSA

<table>
<thead>
<tr>
<th>Site</th>
<th>MHC prevalence</th>
<th>Plasmodium spp. reported</th>
<th>Design</th>
<th>Other significant findings</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adults and nonpregnant women</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lagos, Nigeria</td>
<td>47.5%</td>
<td>P. falciparum, P. malariae</td>
<td>Cross-sectional</td>
<td>Prevalence of malaria higher in HIV-infected vs uninfected subjects (P=0.0047) Anemia prevalence higher in coinfected (258%) vs HIV monoinfected (111%) patients</td>
<td>27</td>
</tr>
<tr>
<td>Bobo-Dioulasso, Burkina Faso</td>
<td>3.09%</td>
<td>NR</td>
<td>Prospective + retrospective</td>
<td>Anemia prevalence higher in coinfected patients</td>
<td>20</td>
</tr>
<tr>
<td>Kano, Nigeria</td>
<td>27.7%</td>
<td>P. falciparum (99.1%)</td>
<td>Cross-sectional</td>
<td>Prevalence of coinfection higher in HIV patients not on ART Prevalence of coinfection lower among patients on Ctx prophylaxis CD4 T-cell count lower in coinfected compared to HIV monoinfected patients (P=0.035) Prevalence lower among regular ITN users (225% vs 429%)</td>
<td>28</td>
</tr>
<tr>
<td>Kinshasa, Congo</td>
<td>20.33%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Female sex, immunosuppression (CD4 T cells &lt;350) and not using ITNs predicted occurrence of clinical malaria in HIV-infected patients</td>
<td>31</td>
</tr>
<tr>
<td>Kpando, Ghana</td>
<td>41%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Anemia prevalence higher among coinfected patients</td>
<td>31</td>
</tr>
<tr>
<td>Nigeria</td>
<td>32.2%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>In-hospital mortality higher in coinfected patients compared to controls (130% vs 17%) More frequent respiratory distress, bleeding disorders, hypoglycemia, and liver and renal failure in coinfected patients</td>
<td>32</td>
</tr>
<tr>
<td>Mozambique</td>
<td>33.02%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Prevalence of severe malaria higher among HIV-infected compared to HIV-negative subjects (617% vs 472%) Lower Hb among coinfected vs HIV monoinfected subjects (P=0.003) Lower prevalence of malaria in HIV-infected persons receiving Ctx prophylaxis</td>
<td>33</td>
</tr>
<tr>
<td>Rwandaa</td>
<td>12.96%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Prevalence of malaria higher in HIV-infected patients, those with lower CD4 T-cell counts, and those not sleeping under ITNs Prevalence of coinfection lower in coinfected patients on Ctx prophylaxis</td>
<td>34</td>
</tr>
<tr>
<td>Ghana</td>
<td>11.75%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Anemia prevalence higher among coinfected patients CD4 T-cell counts lower among coinfected patients</td>
<td>35</td>
</tr>
<tr>
<td>Oromia, Ethiopia</td>
<td>0.7%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Lower prevalence among HIV-infected patients who visit health facility for routine follow-up Prevalence of malaria lower in HIV-infected patients receiving Ctx prophylaxis</td>
<td>36</td>
</tr>
<tr>
<td>Yaoundé, Cameroon</td>
<td>7.3%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Prevalence of malaria higher in HIV-infected patients, those with lower CD4 T-cell counts, and those not sleeping under ITNs Prevalence of coinfection lower in coinfected patients on Ctx prophylaxis</td>
<td>37</td>
</tr>
<tr>
<td>Nigeria</td>
<td>18.5%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Mean Hb and PCV lower among coinfected patients Higher prevalence of coinfection among rural residents Prevalence of anemia higher among coinfected patients compared to HIV-negative subjects</td>
<td>38</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>17.4%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Malaria-parasite density higher in coinfected patients with lower CD4 T-cell count (negative correlation)</td>
<td>39</td>
</tr>
<tr>
<td>Abakaliki, Nigeria</td>
<td>19.4%</td>
<td>P. falciparum (72.6%), P. vivax (27.4%)</td>
<td>Retrospective</td>
<td>Mean CD4 T-cell count and Hb lower in coinfected vs HIV monoinfected patients</td>
<td>30</td>
</tr>
<tr>
<td>Mozambique</td>
<td>72%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Prevalence of malaria higher in HIV-infected patients, those with lower CD4 T-cell counts, and those not sleeping under ITNs Prevalence of coinfection lower in coinfected patients on Ctx prophylaxis</td>
<td>31</td>
</tr>
<tr>
<td><strong>Pregnant women</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethiopiaa</td>
<td>0.94%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Mean CD4 T-cell count and Hb lower in coinfected vs HIV monoinfected patients</td>
<td>40</td>
</tr>
<tr>
<td>Ibadan, Nigeria</td>
<td>22.8%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td></td>
<td>41</td>
</tr>
<tr>
<td>Douala, Cameroon</td>
<td>17.3%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Lower mean Hb among coinfected compared to HIV-monoinfected women</td>
<td>42</td>
</tr>
</tbody>
</table>

(Continued)
handful of studies have reported these.27–30 It is well known that Plasmodium falciparum, which happens to be the most virulent of the plasmodia, is the principal species in circulation in SSA, 3 but today molecular evidence shows that other Plasmodium spp. are increasingly causing malaria in the region. For example, Wondimneneh et al 29 reported a prevalence of P. vivax of 27.4% among MHC patients in Nigeria. A growing number of epidemiological studies are also reporting species other than P. falciparum causing malaria in the general population in SSA. These other species of plasmodia (P. vivax, P. malariae, and P. ovale) may be interacting with HIV differently than previously thought, necessitating further research to provide a clearer picture of malaria and HIV interaction in SSA.

Impact of MHC in SSA

Separately, malaria and HIV have a profound physiological impact on infected patients. 51 In immunocompetent patients, malaria infection produces a spectrum of clinical manifestations of severe anemia, respiratory distress, cerebral malaria, coma, multiorgan failure, or death. 52 Anemia is a common manifestation in SSA, especially in children and pregnant women, and malaria is one of its major causes. 53 HIV, on the other hand, infects and depletes CD4+ T cells, thereby exposing infected patients to opportunistic infections. HIV is also associated with dysregulation of proinflammatory cytokines and chemokines in plasma and lymph nodes, thereby influencing disease progression. 53 Proinflammatory cytokines are known to play an important role in both the control and pathogenesis of both diseases, and are the potential means by which HIV affects the disease course and outcome in other infections, such as malaria. 54 Table 2 presents a summary of the impact of HIV on malaria and vice versa.

Impact on transmission

In coendemic areas, malaria and HIV each have an impact on the transmission of the other. Malaria leads to an increase in the viral load of HIV and hence increases the probability of transmission of HIV, thereby increasing HIV prevalence. 18 This may explain why SSA also has the highest burden of HIV. It has been postulated that without the amplification effect caused by malaria, HIV decreases to extinction. 16 Repeated transient increases in HIV load resulting from coinfection with malaria have been proposed as an important factor in the rapid spread of HIV infection in SSA. 17 Using a mathematical model, scientists were able to estimate that an increase in viral load was associated with a 2.45-fold increase in transmission probability of HIV. 54 However, the effect of malaria on HIV load may not be significant in HIV-infected children compared to adults, as children generally have higher baseline viral loads than adults. Therefore, the relative influence of malaria on HIV load may not be as great. 55

<table>
<thead>
<tr>
<th>Site</th>
<th>MHC prevalence</th>
<th>Plasmodium spp. reported</th>
<th>Design</th>
<th>Other significant findings</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ghana</td>
<td>20.3%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Prevalence higher among HIV-infected patients compared to HIV-negative patients</td>
<td>43</td>
</tr>
<tr>
<td>Nigeria</td>
<td>37.5%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Higher prevalence in HIV-infected women</td>
<td>44</td>
</tr>
<tr>
<td>Rwanda</td>
<td>13.3%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>CD4+ T cells &lt;350 associated with higher risk of coinfection</td>
<td>45</td>
</tr>
<tr>
<td>Nigeria</td>
<td>18.5%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Low birth weight in coinfected women</td>
<td>37</td>
</tr>
<tr>
<td>Children</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ibadan, Nigeria</td>
<td>27.8%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Malaria-parasite density higher in coinfected patients compared to malaria-monoinfected patients</td>
<td>41</td>
</tr>
<tr>
<td>Kenya</td>
<td>12%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Higher prevalence of severe malaria (severe acidosis, anemia, and respiratory distress and higher peripheral blood parasitemia) and mortality in HIV-infected children (26% vs 9%)</td>
<td>39</td>
</tr>
<tr>
<td>Mozambique</td>
<td>11%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yaoundé, Cameroon</td>
<td>1.2%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td></td>
<td>47</td>
</tr>
<tr>
<td>Malawi</td>
<td>15%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td></td>
<td>48</td>
</tr>
<tr>
<td>Sokoto, Nigeria</td>
<td>31%</td>
<td>NR</td>
<td>Cross-sectional</td>
<td>Prevalence of coinfection higher in males</td>
<td>49</td>
</tr>
<tr>
<td>Abidjan, Côte d’Ivoire</td>
<td>18.3%</td>
<td>NR</td>
<td>Cohort study</td>
<td>Higher incidence of malaria in HIV-infected children not receiving Ctx prophylaxis</td>
<td>50</td>
</tr>
</tbody>
</table>

Note: Incidence of malaria per 100 children.
Abbreviations: NR, not reported; Ctx, cotrimoxazole; Hb, hemoglobin; MHC, malaria and HIV coinfection; SSA, sub-Saharan Africa; ITN, insecticide-treated net; ART, antiretroviral therapy; PCV, pack cell volume.
On the other hand, HIV infection increases the incidence of falciparum parasitemia and is associated with severe malaria by mechanisms that involve immunosuppression. In a study involving 41 countries in SSA, HIV infection was thought to have caused an average increase in the prevalence of malaria of 1.3% and malaria-related mortality of 4.9%. The same study also revealed that an extra 3 million cases of clinical malaria and 65,000 malaria-related deaths could be attributable to HIV infection in Africa every year.

The impact of HIV on malaria is modified by such factors as the endemicity and stability of malaria transmission. In areas with stable malaria transmission, HIV has been reported to increase the risk of malaria infection and clinical malaria in adults, especially those with advanced immunosuppression. In settings with unstable malaria transmission, HIV-infected adults are at increased risk of complicated and severe malaria deaths, because natural immunity against malaria is not acquired, resulting in a high proportion of malaria cases. This was evident in a prospective study in South Africa, in which HIV-infected patients were observed to have a fourfold-increased risk of severe malaria. Malaria, on the other hand, has been shown to be significantly associated with HIV infection in eastern SSA, but not in western SSA, suggesting that it might not play an important role in the spread of HIV in populations where the prevalence of HIV is low. Further studies are required to confirm this. Furthermore, in coendemic areas, the interaction between the two diseases may be influenced by their geographical distribution (in situations where HIV is more prevalent in urban areas and malaria in rural areas) and age (where HIV is more in adults and malaria in children).

### Biological and clinical impact of MHC

The biological basis of the interaction between malaria and HIV is well established. As mentioned earlier, malaria has been associated with an increase in viral load, both in vivo and in vitro, and a fall in CD4+ T-cell count, potentially worsening the prognosis of HIV-infected patients and threatening antiretroviral (ARV)-treatment effectiveness. A prospective cohort study performed among HIV1-infected adults in Malawi revealed HIV1 RNA concentration almost doubled between HIV monoinfection and MHC. In the same study, it was estimated that on average, malaria generated a 0.25-log increment on mean HIV RNA concentration. Similar observations have been made among Ugandan children living with HIV/AIDS, in whom malaria was observed to increase transiently the HIV viral load by 0.42 log than that reported in adults. The transient increase in viral load is estimated to last 5–8 weeks (depending on the rate of parasite clearance), but after coinfected parasites have been cleared from the body, the viral load returns to its original viral set point.

The mechanism by which *Plasmodium* infection enhances HIV1 replication is not fully understood, and is thought to be mediated by malaria antigens. One study has shown that the mechanism by which *P. falciparum* induces HIV replication may involve infected red blood cells, which activate CD4+ T cells and stimulate HIV replication in a TNFα-dependent manner following malarial antigen processing by monocytes/macrophages.

HIV-associated immunosuppression contributes to more frequent and more severe malaria, commonly anemia and cerebral malaria, increases the risk of placental malaria in pregnant women regardless of gravidity, and increases the

### Table 2 Summary of the impact of malaria and HIV coinfection

<table>
<thead>
<tr>
<th>HIV impact on malaria</th>
<th>Nonpregnant adults</th>
<th>Children</th>
<th>Pregnant women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased incidence of clinical malaria</td>
<td>4.27,34,38</td>
<td>4.56,58,60</td>
<td>4.13,37,43,51,55</td>
</tr>
<tr>
<td>Increased in malaria-associated mortality</td>
<td>4.22,71</td>
<td>4.29,40,55,74,79,80,84,85,86,87</td>
<td>4.74</td>
</tr>
<tr>
<td>Increased severity of malaria including anemia</td>
<td>4.20,27,29,32,34,35,37,38</td>
<td>4.20,29,43</td>
<td>4.14,15,42,47,49,77</td>
</tr>
<tr>
<td>Increased risk of placental malaria</td>
<td>NA</td>
<td>NA</td>
<td>4.14,15,27,44,58,78</td>
</tr>
<tr>
<td>Increased parasite density</td>
<td>4.19,30</td>
<td>?</td>
<td>4.19,51,55</td>
</tr>
<tr>
<td>Decreased immunity to malaria</td>
<td>4.30,91,96</td>
<td>?</td>
<td>4.93–97</td>
</tr>
<tr>
<td>Impaired antimalarial drug efficacy and/or increase in adverse events</td>
<td>4.43,100,101</td>
<td>?</td>
<td>4.14,15,56,99,103,107,124</td>
</tr>
<tr>
<td>Selection of resistant strains of parasite</td>
<td>4.19,100</td>
<td>4.19</td>
<td>?</td>
</tr>
</tbody>
</table>

### Notes:
- + Supported by five studies or fewer;
- ++ strongly supported by more than five studies;
- ? studies highly inconsistent or not performed.

### Abbreviation:
- MHC, malaria–HIV coinfection.

### Research and Reports in Tropical Medicine 2018:9

Submit your manuscript | www.dovepress.com

For personal use only.
Powered by TCPDF (www.tcpdf.org)
In pregnancy, MHC is associated with higher frequency of clinical malaria and higher parasite density. Maternal mortality is also higher in women with MHC compared to those with single infection. About 1 million pregnancies in SSA are complicated by MHC every year. A Zimbabwean study revealed that malaria-related mortality was higher in HIV-infected patients than HIV-uninfected patients (58% vs 19%).

In pregnancy, MHC is associated with higher frequency of clinical malaria and higher parasite density. Maternal mortality is also higher in women with MHC compared to those with single infection. About 1 million pregnancies in SSA are complicated by MHC every year. A Zimbabwean study revealed that malaria symptoms were about four times as likely to develop in HIV-infected pregnant women than in those without HIV. Pregnant women with MHC are at increased risk of low birth weight and preterm delivery, higher rates of neonatal mortality, placental malaria infection, severe anemia, slow gestational development, reduced transfer of maternal antibodies (conferring protection against other infections) from mother to child, and in some settings increased risk of mother–child transmission of HIV.

The risk to the woman and her newborn exists regardless of the number of times a woman has given birth. First pregnancies are often the most critical, as women develop pregnancy-specific immunity against placental parasites over successive pregnancies (due to repeated exposure). However, available data suggest that women who are living with HIV have the same low level of immunity to malaria in subsequent pregnancies as they do in their first pregnancy and are twice as susceptible to clinical malaria, which increases the risk of adverse outcomes. A cohort study conducted in western Kenya demonstrated that MHC more than doubled the risk of moderate–severe anemia in pregnant women. Furthermore, most studies have reported increased frequency of placental malaria in HIV-infected women, which increases with parity. A review of eleven studies in Africa revealed that the proportion of cases of placental malaria attributable to HIV coinfection increased with the number of pregnancies: 21.3%, 41.2%, and 58.2% for the first pregnancy, second pregnancy, and more than two pregnancies, respectively. Infant mortality is also high in children born to MHC mothers, but this has not been confirmed in subsequent studies.

In children, more frequent episodes of clinical malaria have been observed in those HIV-infected compared to HIV-uninfected children, and this increases with the severity of immunosuppression. MHC children have been observed to present with more severe forms of malaria, such as severe acidosis, anemia, respiratory distress, higher parasite density and plasma P. falciparum histidine-rich protein, cerebral malaria, and higher case-fatality rates compared to single infection. Results from a prospective study of children with severe malarial anemia needing blood transfusion indicated a higher risk of death at day 7 (HR 2.86), day 28 (HR 3.70), and month 6 (HR 5.70) after treatment in HIV-infected children compared with HIV-uninfected children. Moreover, Kenyan study also revealed mortality at 3 months after malaria was higher in HIV-infected children compared to HIV-uninfected children (33% vs 3%).

Immunological impact of MHC

Malaria immunity is characterized by an age-related reduction in parasite burden, clinical symptoms, and prevalence of severe malaria in individuals residing in endemic areas. Malaria is often less severe in older adults than in children because of their immunity, which increases with increasing age. Children are thus at increased risk of severe malaria, since they have not yet acquired natural immunity. Pregnant women, particularly primigravid women, transiently lose some of their acquired immunity too.

Available data show conclusively that malaria and HIV infection interact to bring about dysregulation of the immune system. Independently, HIV and malaria interact with the host immune system to bring about complex activation of immune cells, which causes dysfunctional levels of cytokine and antibody production. In addition, CD4+ T cells play a major role in the development and maintenance of antimalaria immunity, but HIV interferes with this immunity, the mechanism of which includes widespread lymphoid necrosis throughout the lymph nodes, spleen, and gut mucosae, hyperactivation of CD4+ and CD8+ effector cells to secrete cytokines, HIV-induced downregulation of CD4+ T cells, decreases in CD8+ T-cell counts, and upregulation of parasitemia, consequently leading to fatal malaria and a rapid progression to AIDS. In one study, HIV infection was observed to be associated with marked blunting of the inflammatory response in a cohort of cerebral malaria in Malawian children. In another study using simian HIV–
between placental malaria and PDGFRα expression.

The results suggest that PDGFRα expression is associated with placental malaria, and its expression may be a potential target for the treatment of placental malaria.

**Therapeutic impact of MHC**

MHC also has a negative impact on the efficacy of antimalarial and/or ARV drugs in patients concomitantly receiving malaria treatment or preventive therapy for malaria and ARV or prophylactic medicines for HIV infection. HIV infection has been observed to impair the protection offered by antimalarial treatment and increases the occurrence of adverse events, as well as the selection of mutant strains associated with antimalarial drug resistance. In malaria-endemic areas where HIV prevalence is also high, interaction with ARV drugs, especially protease inhibitors, could affect the utilization of newly introduced artemisinin-based combination therapy (ACT). Adverse events associated with artesunate/amodiaquine (AS/AQ), including neutropenia, malaise, and anorexia, have been shown to be higher among patients who were concomitantly receiving ARV therapy (ART). A pharmacokinetic study involving artemether–lumefantrine (AL)- and nevirapine-based ART revealed that nevirapine-based ART decreased artemether and dihydroartemisinin area under the plasma concentration–time curve, but unexpectedly increased lumefantrine exposure. Similar observations have been made for efavirenz. These interactions may increase the risk of malaria-treatment failure and development of resistance to AL and nevirapine. Antimalarial treatment failure may be more common in HIV-infected adults with low CD4+ T-cell counts compared to HIV-uninfected adults.

In a randomized control trial that compared sulfadoxine–pyrimethamine (SP) with AL for uncomplicated malaria, patients with CD4+ T-cell counts <300 cells/μL had an increased risk of recurrent malaria (RR 2.24) and recrudescence (RR 1.67), but recent studies have failed to confirm this. As pointed out by Flateau et al, impaired acquired immunity in HIV-infected adults but not in children could be responsible for this, as response to treatment also depends on host immunity. In another study, the efficacy of chloroquine and SP in reducing placental malaria in pregnant HIV1-infected women was impaired compared to pregnant HIV1-negative women. A preliminary study conducted on pregnant women in Mali revealed that 50% with acute malaria who were concomitantly on nevirapine and quinine had lower therapeutic level of quinine than that recommended. The same study also found higher concentrations of the quinine’s metabolite, 3-hydroxyquinine, suggesting that nevirapine impaired the activity of quinine. In addition, when given...
concomitantly in pregnancy, SP and daily nevirapine can potentially cause fatal liver and skin toxicity. Severe cutaneous reactions (including Stevens–Johnson syndrome) and clinical hepatitis have been reported in approximately 2% and 4%, respectively, of patients taking daily nevirapine. Furthermore, hepatotoxicity has been observed to occur more frequently in women with higher CD4+ T-cell count. Other ARV drugs have also been reported to interact with antimalarial drugs, including zidovudine, in which higher mortality rates have been observed in HIV-infected patients, especially those with anemia at baseline. The impact of drug–drug interaction in MHC could be beneficial (in the case where one of the drugs for either malaria or HIV acts synergistically to inhibit the progression of the other). Several studies have shown that protease inhibitors (PIs) can impede the growth of malaria parasites at concentrations that may be of clinical significance. For example, the PIs ritonavir and lopinavir have been observed to inhibit the preerythrocytic and erythrocytic stages of the malaria parasites in vivo and in vitro. The efficacy of PIs have also been observed to depend on the infecting parasite species. For example, Lek-Uthai et al showed that ritonavir was four times as effective at inhibiting \( P \) \_\_\_ \_ \_ than it was when administering \( P \) \_\_\_\_\_\_ in the laboratory. For example, one study revealed that chloroquine is capable of inhibiting HIV replication however, the clinical implications of these findings remain largely undefined.

Drug–drug interaction between antimalarials and ART could also be deleterious (in the case where one of the drugs antagonizes another and facilitates the progression of the other disease). For example, pyrimethamine has been observed to enhance HIV1 replication significantly in a mechanism that increases HIV Gag proteins without affecting the promoter or reverse-transcriptase activity. Another deleterious effect of drug–drug interaction is the selection for resistant strains of the parasite. For example, studies have reported elevated day 7 lumefantrine concentration and persistent parasitemia, with strong selection for the Pfmdr1 codon 86N allele among treated HIV subjects on nevirapine, which is a strong indicator for AL-treatment failure or slow clearance in vivo.

Treatment strategy for MHC

Treatment of malaria

ACTs containing a combination of either AL, AS–AQ/mefloquine/SP, or dihydroartemisinin–piperine are the recommended treatment for malaria in SSA. Unlike in Southeast Asia, resistance to ACTs has not been reported in SSA. However, resistance has been reported with other antimalarial drugs, including chloroquine and SP in SSA. In some Asian countries, including India, \( P \) \_\_\_\_\_\_ MHC patients have been shown to respond 100% to malaria treatment. Contrarily, in SSA, HIV is thought to affect the efficacy of antimalarial drugs negatively. However, such findings are greatly constrained by small samples and are thus inconclusive. Moreover, this is now known to be due to re-infection with new malaria strains, rather than recrudescence of prior infection. AL, dihydroartemisinin–piperine, and AS/AQ have all been shown to be 100% efficacious for treating malaria in HIV-infected patients in SSA, notwithstanding the adverse events observed with AS/AQ. AL has been shown to be efficacious and well tolerated in children in Uganda. Another study has shown that dihydroartemisinin–piperine is superior to AL in preventing recurrent parasitemia. Although there is a wealth of studies showing the potential interaction between ACT and ART, the current evidence is insufficient to modify the general treatment plan for patients with HIV/AIDS. However, because of adverse events, the World Health Organization (WHO) recommends that treatment in HIV-infected patients on zidovudine or efavirenz should if possible avoid AQ-containing ACT regimens, as this increases the risk of neutropenia and hepatotoxicity.

Prevention of malaria in pregnant HIV-infected women

Pregnant HIV-infected women and their infants are the least protected against malaria, despite being the most vulnerable population. Intermittent preventive treatment in pregnancy (IPTp) with SP, a highly effective and recommended approach for preventing pregnancy-related malaria and its complications, is contraindicated for HIV-infected women receiving ART and cotrimoxazole (Ctx; trimethoprim–sulfamethoxazole) prophylaxis for opportunistic infections, due to the risk of sulfonamide-induced adverse drug reactions. This has been demonstrated in clinical trials, eg, in one trial of twice-weekly SP for AIDS-related opportunistic infections, 6.3% (6 of 65) of patients required discontinuation because of adverse reactions. Other studies have also reported fatal reactions to SP.

In pregnant women not on Ctx, more than two doses of SP are required to achieve the same benefit as two doses of SP in HIV-negative women. This has been corroborated in more than one study. One prospective cohort study comparing three IPTp regimens with SP (presumptive treatment of fever, two treatments during pregnancy, or monthly treatment) revealed...
that only monthly treatment achieved the same efficacy on placental malaria in HIV-infected and -uninfected women.\textsuperscript{122} In another, monthly treatment with SP reduced the risk for placental malaria by 64\% and the risk of clinical malaria by 66\% in HIV-infected pregnant women compared to two treatments. However, the clinical benefit of monthly treatment vs two doses on premature delivery, low birth weight, and perinatal mortality still needs to be evaluated. In addition, the efficacy of IPTp with SP in women in their first or second pregnancies has been shown to be conserved even in areas of SP resistance,\textsuperscript{123} and is thus recommended in highly endemic areas of SP resistance in combination with insecticide-treated nets (ITNs).\textsuperscript{14}

In the absence of SP, the WHO recommends daily Ctx for pregnant immunocompromised HIV-infected women.\textsuperscript{14} Daily use of Ctx has been shown to be efficacious in reducing the incidence of malaria in children and nonpregnant adults. However, there are constraints that may limit its use in pregnant women, including late diagnosis, delay in initiation, fear of the emergence of resistance, and the intolerance, observed with many HIV-infected patients.\textsuperscript{14} Moore et al reported the risk of adverse reaction to Ctx as 26.3 per 100 person-years, and the risk increases with advancing immunosuppression.\textsuperscript{124} There is thus a need to evaluate alternative antimalarial drugs for use in HIV-infected pregnant women, since IPTp with SP is contraindicated in pregnant women.\textsuperscript{99} Suitable drugs for IPTp must be safe for both the mother and the fetus, able to be given during regular antenatal care visits, and provide long-lasting protection.

Prevention of malaria in HIV-infected children

In children, there is no indication that HIV impairs clinical and parasitological responses to treatment in uncomplicated malaria, even in those with low CD4\(^+\) T-cell counts.\textsuperscript{103,125–127} Ctx as a prophylaxis is also effective in protecting children against malaria in areas of stable malaria transmission. One study showed that HIV-infected children receiving daily Ctx had an 80\% reduced risk of clinical malaria compared to HIV-uninfected children not receiving Ctx.\textsuperscript{19} However that study observed Ctx to be associated with infection with parasites with a rare mutation, dhfr164L, known to mediate high-level antifolate resistance.\textsuperscript{19} Contrary to this is a study conducted in Uganda that showed that although resistance rates of \textit{P. falciparum} to antifolate drugs are high, Ctx prophylaxis in HIV-infected persons was not associated with a higher prevalence of mutations associated with antifolate resistance.\textsuperscript{128} Many other studies have shown that Ctx lowers the risk of clinical malaria in both adults and children with HIV (Table 1).\textsuperscript{5,50} Moreover, adverse events, including moderate–severe neutropenia, have been reported to be more frequent in HIV-infected children receiving Ctx, ART, and AS/AQ concurrently.\textsuperscript{127} Other studies conducted in Mali and Kenya have also found the efficacy of Ctx to be conserved.\textsuperscript{129,130} Ctx prophylaxis combined with ITNs has been observed to reduce the prevalence of clinical malaria in HIV-infected children by 97\% compared to 43\% for ITNs alone.\textsuperscript{115} Therefore, these drugs should be provided as widely and durably as possible.

Treatment of HIV

ARTs in current use are classified as nucleoside reverse-transcriptase inhibitors, nonnucleoside reverse-transcriptase inhibitors, and PIs. Although studies have demonstrated that PIs are able to inhibit the malaria parasite in vitro and in animals, this has not been proven in human studies.\textsuperscript{15,131–133} However, PIs have been shown to have synergistic effects with chloroquine and mefloquine on \textit{P. falciparum} and \textit{P. chabaudi} in vitro,\textsuperscript{132,134,135} whereas data on interactions with artemisinin are inconsistent.\textsuperscript{136,137} The potential benefits of PIs in the prevention of malaria was demonstrated in a study conducted on Malawian children (aged 4–62 months) in which children on lopinavir–ritonavir in combination with malaria treatment showed a lower risk of recurrent positive blood smear compared to those on zidovudine, lamivudine, and nevirapine.\textsuperscript{138} Another study also found a 41\% reduction in malaria incidence in children receiving lopinavir–ritonavir.\textsuperscript{139} ART combined with Ctx has also been reported to reduce the frequency of clinical malaria by 92\% compared to 76\% for Ctx alone.\textsuperscript{140} These findings suggest that ART (especially PIs) are important in the management of malaria in MHC, and are thus recommended.

Access to ART is also a key factor in the management of MHC. As mentioned earlier, malaria tends to increase the HIV load, which in turn increases the probability of vertical transmission, especially in pregnant women.\textsuperscript{14} Increased access to ART may serve as a means of mitigating the harmful effects of malaria in MHC.\textsuperscript{16} However, factors that adversely impact treatment outcomes in SSA, including low adherence, poor-quality drugs, resource scarcity, lack of infrastructure, and inadequate treatment, persist in most of the region.\textsuperscript{44}

Conclusion

Available data show a high prevalence of MHC in SSA, which varies considerably from one geographical setting to another. There is sufficient evidence to show that HIV increases the prevalence and severity of clinical malaria in
adults and children, increases the risk of placental malaria in pregnancy, and undermines malaria treatment in adults and pregnant women. On the other hand, malaria increases the probability of HIV transmission from pregnant mothers to their children and hastens the progression of HIV to AIDS. Furthermore, in coendemic areas, malaria and HIV exert a negative impact on each other in terms of their biological, clinical, and immunological interaction, as well as potential adverse drug–drug interaction that threaten the efficacy of treatment of MHC patients. The high prevalence of coinfection in SSA thus presents a double blow to the region, which is presently worst hit by the presence of other infectious diseases, including tuberculosis. To overcome the burden of MHC will require a number of strategies.

Firstly, increase access to Ctx prophylaxis and ART. HIV-infected patients who visit the hospital more often with intervals of less than a month have significantly lower odds of coinfection. Increasing access to treatment facilities will go a long way to curb the burden of malaria in HIV-infected persons. Secondly, there is an urgent need for improvement in malaria control, especially in pregnant women. Malaria control, which can be achieved chiefly by vector control using ITNs and residual spraying, has also been shown to be an effective strategy to curb HIV prevalence. For example, a recent study in Kenya demonstrated that providing long-lasting insecticide-treated bed nets and water filters to HIV-positive adults with CD4+ T-cell counts >350 cells/mm³ significantly reduced the progression of HIV, deferred time to ART eligibility, and saved US$26 million. Control of malaria is thus a practical and cost-saving method that could easily be applied in resource-constrained settings, which characterizes most rural areas in SSA.

Thirdly, empirical studies are needed to unlock the mechanism of interaction between malaria and HIV, particularly at the biological level. Studies that have been conducted so far were seriously skewed toward understanding the effect of HIV on malaria, ignoring the effect of malaria on HIV. Lastly, there is a need to accelerate research in the development and field testing of vaccines against malaria and HIV. Considerable progress has been made in the development of a malaria vaccine, and today we have a malaria vaccine – RTS,S/AS01 (Mosquirix). An HIV vaccine has also been developed (RV144) and a Phase III trial in Thailand showed an efficacy of 31%. So far, this is the only promising HIV vaccine, and further research is needed in the development of others. A study using models showed that vaccinating macaques with recombinant Listeria Δact A prfA* expressing simian/HIV (sHIV) was protective against life-threatening sHIV-related malaria after sHIV–P. fragilis coinfection. No study has been conducted to determine the efficacy of these malaria or HIV vaccines in protection against MHC in humans. Human trials are thus required in SSA.

Disclosure

The author reports no conflicts of interest in this work.

References


Kwenti


